NewsSource: EClinCloud

Invitation | Join Us in Suzhou on March 21–24 for the 2024 CMAC Annual Conference

1 min readEClinCloud Editorial Team
Invitation | Join Us in Suzhou on March 21–24 for the 2024 CMAC Annual Conference — news header image

Source: EClinCloud. Author: EClinCloud.

Article image





About EClinCloud

EClinCloud is a technology company focused on clinical research and development. It provides an integrated, interoperable clinical trial cloud platform (including solutions across technology products and offerings such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, covering scale design, scale copyright management, linguistic validation, rater training, and data quality analysis, among others) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system and ophthalmology, among others). By combining frontier technology with life sciences data, EClinCloud builds a globally leading, patient-centric SaaS cloud platform for clinical evidence support, helping pharmaceutical companies and research institutions in China and abroad improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.







Article image

Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.